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Photosensitivity is a heritable abnormal cortical response to ﬂickering light, manifesting as particular electroencephalographic
changes, with or without seizures. Photosensitivity is prominent in a very rare epileptic encephalopathy due to de novo CHD2
mutations, but is also seen in epileptic encephalopathies due to other gene mutations. We determined whether CHD2 variation
underlies photosensitivity in common epilepsies, speciﬁc photosensitive epilepsies and individuals with photosensitivity without
seizures. We studied 580 individuals with epilepsy and either photosensitive seizures or abnormal photoparoxysmal response on
electroencephalography, or both, and 55 individuals with photoparoxysmal response but no seizures. We compared CHD2 se-
quence data to publicly available data from 34427 individuals, not enriched for epilepsy. We investigated the role of unique
variants seen only once in the entire data set. We sought CHD2 variants in 238 exomes from familial genetic generalized epilepsies,
and in other public exome data sets. We identiﬁed 11 unique variants in the 580 individuals with photosensitive epilepsies and 128
unique variants in the 34427 controls: unique CHD2 variation is over-represented in cases overall (P =2 17  10
5). Among
epilepsy syndromes, there was over-representation of unique CHD2 variants (3/36 cases) in the archetypal photosensitive epilepsy
syndrome, eyelid myoclonia with absences (P =3 50  10
4). CHD2 variation was not over-represented in photoparoxysmal
response without seizures. Zebraﬁsh larvae with chd2 knockdown were tested for photosensitivity. Chd2 knockdown markedly
enhanced mild innate zebraﬁsh larval photosensitivity. CHD2 mutation is the ﬁrst identiﬁed cause of the archetypal generalized
photosensitive epilepsy syndrome, eyelid myoclonia with absences. Unique CHD2 variants are also associated with photosensitivity
in common epilepsies. CHD2 does not encode an ion channel, opening new avenues for research into human cortical excitability.
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Introduction
Photosensitivity is a heritable abnormal cortical response
to ﬂickering light, often manifesting as EEG changes called
a photoparoxysmal response (Walter et al., 1946).
Photoparoxysmal response may occur with seizures, and in
normal subjects, or with neuropsychiatric disorders (So et al.,
1993). The photoparoxysmal response is age-dependent:
prevalence in healthy children is between 1.4 and 8.3%, drop-
ping to 51% in adults (Gregory et al., 1993; Quirk et al.,
1995; Kasteleijn-Nolst Trenite et al.,2 0 0 3 ;V e r r o t t iet al.,
2012). Photosensitive epilepsy is a reﬂex epilepsy, with seiz-
ures triggered by visual stimuli. A population-based study in
Great Britain determined that the annual incidence of epilepsy
with photoparoxysmal response was 1.1 per 100000 in the
overall population, and 5.7 per 100000 between 7 and 19
years of age (Quirk et al., 1995). About 40% of people with
photosensitive epilepsy only have seizures on exposure to
visual stimuli. Photosensitive seizures also feature in speciﬁc
epilepsy syndromes, with other seizure types, and in non-
syndromic epilepsies. Examples include juvenile myoclonic
epilepsy (Tauer et al., 2005; Koeleman et al., 2013; Taylor
et al., 2013), other genetic generalized epilepsies (GGE)
(Taylor et al., 2013), idiopathic photosensitive occipital
epilepsy, and other focal (Taylor et al., 2004; Lu et al.,
2008), symptomatic occipital, and progressive myoclonic, epi-
lepsies. The archetypal photosensitive syndrome is eyelid myo-
clonia with absences (EMA), a GGE characterized by rapid
eyelid jerks and upward eyeball deviation on eye closure:
photosensitivity is an essential feature (Sadleir et al., 2012).
The photoparoxysmal response is highly heritable (Waltz
and Stephani, 2000; Tauer et al., 2005; Taylor et al.,
2013). The genetics are complex: no single gene has been
implicated despite linkage to several loci and formal meta-
analysis (Tauer et al., 2005; De Kovel et al., 2010; Verrotti
et al., 2012). Photosensitive epilepsies also have complex
genetic architecture (Sadleir et al., 2012; Taylor et al.,
2013), with several linked loci (De Kovel et al., 2010).
Photosensitivity is a trait found in many syndromes, inher-
itable separately from epilepsy (Newmark and Penry,
1979). It is unclear whether isolated photoparoxysmal re-
sponse is a risk factor for epilepsy (De Kovel et al., 2010;
Verrotti et al., 2012).
Photosensitivity occurs in some epileptic encephalopa-
thies, such as Dravet syndrome due to mutation in
SCN1A and encephalopathy associated with mutation in
CHD2 (Carvill et al., 2013). Published data do not allow
determination of whether the photosensitivity in these con-
ditions is due to the underlying gene mutation or to the
epileptic encephalopathy per se. CHD2 encodes chromodo-
main helicase DNA-binding protein 2, involved in tran-
scriptional regulation. Additional attention was drawn to
CHD2 as a candidate photosensitive epilepsy gene as the
only shared gene within several reported overlapping copy
number variants of the chromosome 15q26.1 region asso-
ciated with complex phenotypes including epilepsy with
photosensitivity. Eight patients with de novo deletions of
15q26 encompassing part or all of CHD2 have been re-
ported (Veredice et al., 2009; Dhamija et al., 2011; Capelli
et al., 2012; Lund et al., 2013; Mullen et al., 2013; Che ´nier
et al., 2014). We and others subsequently showed 6/500
epileptic encephalopathy cases had de novo CHD2 muta-
tions (Carvill et al., 2013; Epi4K Consortium et al., 2013;
Suls et al., 2013; Lund et al., 2014), and recently showed
that clinical photosensitivity was prominent in the rare
CHD2-associated myoclonic encephalopathy (Thomas
et al., 2015).
These ﬁndings led us to hypothesize that CHD2 disrup-
tion would be associated with common forms of photo-
sensitive epilepsy or photosensitivity manifesting as a
photoparoxysmal response alone.
Materials and methods
Written informed consent was obtained from patients or
parents/guardians for minors or those with intellectual disabil-
ity. The study was approved by relevant institutional ethics
committees.
We deﬁned photosensitive epilepsy as the presence of a
photoparoxysmal response (Kasteleijn-Nolst Trenite ´ et al.,
2012) with a history of epilepsy, or seizures reproducibly
induced by ﬂickering light. The photoparoxysmal response
per se was not an essential inclusion requirement in every
patient with epilepsy because age, state (e.g. sleep deprivation)
and antiepileptic medication affect its detectability. To test the
effect of CHD2 variation beyond the epileptic encephalopa-
thies alone, we included a broad range of epilepsy types.
Recruitment was from nine countries (see Supplementary
1200 | BRAIN 2015: 138; 1198–1207 E. C. Galizia et al.
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 material for details) (Tauer et al., 2005; Lu et al., 2008; Taylor
et al., 2013). The cohort included 36 patients with EMA: all
had photoparoxysmal response. We sequenced CHD2 in 580
people with photosensitive epilepsy and 55 people with photo-
paroxysmal response but no history of seizures. All patients
were of European ancestry. The phenotypic distribution is
given in Table 1.
We evaluated data from two additional exome-sequenced
cohorts of GGE patients, to determine the role of CHD2
variation in GGE per se, independent of photoparoxysmal
response. Not all patients in these cohorts had been formally
assessed for photoparoxysmal response. These two groups
were the Complex Genetics of Idiopathic Epilepsies
Consortium (CoGIE) cohort of 238 probands with familial
GGE (Supplementary material), and a published cohort of
118 patients with GGE (Heinzen et al., 2012).
Targeted sequencing of CHD2 was undertaken either using
Illumina TruSeq Custom Amplicon
TM (TSCA) or molecular
inversion probes (see Supplementary material for details).
Whole exome sequencing (Supplementary material) was per-
formed on ﬁve EMA samples. Coverage data for all experi-
ments are provided in the Supplementary material. Only
variants conﬁrmed by a second method (Sanger sequencing
or a second independent molecular inversion probe capture,
see Supplementary material) were used in analyses.
The Exome Aggregation Consortium (ExAC) formed a large
control population of disease and population genetic studies
(ExAC, Cambridge, USA; URL: http://exac.broadinstitute.org
accessed October 2014; non-Finnish European samples only
used), giving the best available population frequency of
CHD2 variants of interest. Detailed phenotypic data are not
available for these individuals; some might, if tested, have or
have had photoparoxysmal response or a history of photo-
sensitive seizures. These unselected cases are unlikely to har-
bour more than the best estimates of photoparoxysmal
response prevalence in the general population (1.4%)
(Kasteleijn-Nolst Trenite et al., 2003).
We focused on unique variants, in our cohort and in ExAC:
this is a well-established approach (Carvill et al., 2013;
Cnossen et al., 2014; Wain et al., 2014). We hypothesized
an over-representation of unique variants in our cohort com-
pared with the phenotypically-unselected ExAC cohort.
We deﬁned unique variants as those that occurred in one
individual only, in cases and controls (from ExAC) considered
together, that were non-synonymous, splice-site or frameshift.
We used several methods for prediction of the functional con-
sequences of unique variants in cases (Supplementary mater-
ial). We deﬁned ‘rare’ variants as those with a minor allele
frequency 51% in the non-Finnish European ExAC samples.
We undertook functional studies. To test functional conse-
quences of Chd2 loss in zebraﬁsh, we used the chd2 E2I2
morpholino reported previously (Suls et al., 2013). Brieﬂy,
morpholino (12ng) was microinjected into 1- to 2-cell-stage
embryos of the AB (wild-type) strain. Embryos were raised
in a dark incubator. At 1 day post-fertilization (dpf), embryos
were prepared using the least possible amount of light. In par-
allel, control non-injected embryos from the same clutch of
eggs were processed in the same manner. At 4 dpf, optic
tectal ﬁeld recordings were performed (Suls et al., 2013)
(Supplementary material). The ﬁrst 10s of recording were
performed in minimal light in order to place the needle.
Immediately following these ﬁrst 10s, recordings were
performed in the dark for ﬁve minutes. At the end of this 5-
min period, a very bright light was switched on (‘light ON’
state; six times the standard brightness level used for needle
placement), and recording continued for 5min. A paroxysm of
high-frequency activity (200–500 Hz) with amplitude 43
times background level, either spontaneous or evoked by
light, was deﬁned as a polyspiking episode.
Statistics
We performed a two-tailed Fisher’s exact test to determine
whether the burden of unique variants in our case cohorts
was greater than expected compared to ExAC controls.
We examined the frequency of all rare variants in the entire
cohort, and the frequency of unique variants only separately in
patients with EMA, patients with GGE excluding EMA, and
patients with focal epilepsies. The threshold for signiﬁcance
was set at P5001, applying Bonferroni correction for these
ﬁve comparisons. For the single separate comparison of cases
with photoparoxysmal response without epilepsy and ExAC,
signiﬁcance was set at P5005. For zebraﬁsh data, compari-
son of the parameters of spiking activity (dark versus light
condition) for each treatment group was performed using the
Mann-Whitney test.
Results
We identiﬁed 22 rare variants (Supplementary Table 1) in
the cohort of patients with photosensitive epilepsy: 11 were
unique (Table 2). There was a signiﬁcant difference
(P = 2.17  10
5) in unique variant frequency between
cases (11/580 cases; 11/1160 alleles; 0.95%) and controls
(128/68854 alleles; 0.19%). The unique variants in the
cases were all well covered in ExAC controls
(Supplementary material). The 11 unique variants in cases
were also absent from additional data sets: Exome Variant
Server (http://evs.gs.washington.edu/EVS/), 1000 Genomes
data set (http://www.1000genomes.org/), and dbSNP
Table 1 Distribution of cases by continental origin and
broad syndromic classiﬁcation
Syndrome
Cohort GGE Focal Other PPR without
epilepsy
European 249 24 32 55
Australian 230* 35* 11 0
Total 479* 59* 43 55
European includes epilepsy cases from Germany (90), Italy (82), The Netherlands (75),
Greece (34), Serbia (17), UK (5) and Denmark (2).
GGE = genetic generalized epilepsies, including GGE for which other information was
not available, and, where classiﬁed, juvenile myoclonic epilepsy, juvenile absence epi-
lepsy, childhood absence epilepsy, early-onset absence epilepsy, epilepsy with myo-
clonic atonic seizures, epilepsy with generalized tonic-clonic seizures only, and EMA.
Focal includes all types of focal epilepsies, including idiopathic photosensitive occipital
lobe epilepsy (IPOE). *One Australian patient evolved from a GGE to a focal epilepsy.
Other includes Lennox-Gastaut syndrome, epilepsy due to tuberous sclerosis, epilepsy
with electrical status epilepticus in sleep and epilepsies otherwise unclassiﬁed: none of
these particular cases had unique CHD2 variants.
CHD2 in photosensitive epilepsy BRAIN 2015: 138; 1198–1207 | 1201
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 (http://www.ncbi.nlm.nih.gov/SNP). There was no differ-
ence in the overall burden of rare CHD2 variants in
cases compared to controls [22/1160 alleles (1.90%)
versus 1236/68854 alleles (1.80%) respectively; P = 0.74].
We provide data on the frequency of variants in CHD2 in
cases and controls according to various thresholds in the
Supplementary Table 2. Figure 1 shows all previously-
reported variants and all unique variants identiﬁed in our
cases.
We investigated the predicted deleteriousness of the 11
unique variants in the cases (Table 2). Eight of 11 unique
variants (73%) had scaled CADD scores 410, placing them
in the top 10% most deleterious single nucleotide variants;
as a group, the 11 variants had a mean scaled CADD score
of 32.6, ranking higher than 99.95% of all possible human
single nucleotide variants (Kircher et al., 2014).
Next, we analysed variation by epilepsy type. The arche-
typal photosensitive GGE syndrome EMA had the highest
frequency of unique variants, found in 3/36 patients, more
than expected compared to ExAC controls (3/72 alleles
versus 128/68854 alleles) (P = 3.50  10
4). As a post
hoc comparison, the frequency of unique variants (4.2%)
in the small EMA group is considerably greater than in our
overall cohort excluding EMA (0.74%) (P = 0.026).
Notably, two of three EMA variants were frameshift, com-
pared to 9/128 unique variants in ExAC. One EMA variant
was shown to have arisen de novo, strengthening its role in
causation of the phenotype.
For all GGE excluding EMA, we found no signiﬁcant
difference compared to ExAC (4/888 alleles versus 128/
68854 alleles, P = 0.089). We also did not ﬁnd signiﬁcant
over-representation in focal epilepsies compared with ExAC
(2/118 alleles versus 128/68854 alleles; P = 0.021). One
case was included in both GGE and focal epilepsy cohorts,
as the phenotype evolved from early-onset absence epilepsy
to idiopathic photosensitive occipital epilepsy (Patient 11,
Table 2). One of 55 (1.82%) individuals with photoparox-
ysmal response but no seizures had a unique CHD2
variant (Table 2 and Fig. 1): this did not represent over-
representation compared to ExAC (1/110 alleles versus
128/68854 alleles; P = 0.186). This case has not developed
epilepsy by the age of 18 years. We provide 99% conﬁ-
dence intervals (CI) (accounting for multiple comparisons)
for all these comparisons in Table 3.
To investigate whether CHD2 may be associated with the
broader phenotype of GGE rather than photosensitive
epilepsies speciﬁcally, we tested whether rare variants in
CHD2 were enriched in patients with GGE, with or
Table 2 Patients found to have unique mutations in CHD2 and their clinical phenotypes
Case
ID
Position
(NCBI.37)
Consequence cDNA change Protein
change
Computational
Analysis
Score (PolyPhen-2;
SIFTindel; SIFT;
splice-site
inference)
CADD
scores
(PHRED
scaled)
Syndromic
diagnosis
Comments
1 15:93545502 Frameshift
deletion
c.4233_4236del p.E1412Gfs*64 Deleterious (0.858) 44 GGE
2 15:93487750 Splice site c.1153+5G4A NA No change in donor site 8.124 Unclassiﬁed
3 15:93541780 Missense c.C3937G p.R1313G Probably damaging (0.98) 16.9 Unclassiﬁed
4 15:93543742 Missense c.G4009T p.A1337S Benign (0.001) 8.728 IPOE
5 15:93496808 Splice site c.1719+5G4A NA Loss of donor site 15.74 Unclassiﬁed Learning disability
6 15:93528855 Missense c.G3365C p.S1122T Benign (0.01) 4.373 GGE
7 15:93540316 Frameshift
deletion
c.3725delA p.K1245Nfs*4 Deleterious (0.858) 43 EMA Autism;
nephrolithiasis;
migraine; scoliosis
8 15:93545442 Frameshift
insertion
c.4173dupA p.Q1392Tfs*17 Deleterious (0.85) 38 EMA De novo mutation
9 15:93482909 Missense c.C653T p.P218L Probably damaging (0.99) 21.3 EMA Inherited from
unaffected
mother
10 15:93543767 Missense c.G4034A p.R1345Q Possibly damaging (0.8) 33 JME
11 15:93563244 Nonsense c.C4909T p.R1637X Probably damaging
(nonsense)
49 Phenotype
evolved
from
early-onset
absence
epilepsy
to IPOE
De novo mutation
i 15:93552396 Missense c.G4435A p.V1479M Probably damaging (0.996) 27.9 PPR; febrile
seizures
only;
no epilepsy
IPOE = idiopathic photosensitive occipital epilepsy; JME = juvenile myoclonic epilepsy; PPR = photoparoxysmal response.
1202 | BRAIN 2015: 138; 1198–1207 E. C. Galizia et al.
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 without photoparoxysmal response. Of 238 CoGIE GGE
probands (Supplementary material), none had unique
CHD2 variants (not seen in ExAC or our cases). There
were no unique mutations in CHD2 in a previously-
published cohort of 118 patients with GGE (Heinzen
et al., 2012).
To test functional consequences of Chd2 loss in zebra-
ﬁsh, we used the chd2 E2I2 morpholino reported previ-
ously (Suls et al., 2013). As described, chd2 morpholino-
injected larvae displayed body curvature, excessive body
pigmentation, and developmental delay (Suls et al.,
2013). This phenotype was observed after 50% knock-
down of chd2. All non-treated larvae appeared normal.
Recordings were obtained from 15 morpholino-injected
larvae and 10 sibling controls. In comparison to 7 dpf
larvae (Afrikanova et al., 2013), spikes from 4 dpf
larvae were shorter in duration and displayed a higher
frequency of oscillations in polyspike complexes. Due to
these differences, spontaneous spiking in controls was not
excluded, but also quantiﬁed. We analysed duration of
discharges, number of discharges under light conditions,
cumulative duration of spiking activity, and cumulative
discharge frequency distribution. Representative recordings
are shown in Fig. 2.
In line with the previous ﬁndings (Suls et al., 2013), the
morpholino-injected larvae showed spontaneous abnormal
burst discharges. There was a preferential occurrence
during the light ON state (17 discharges in the dark
versus 59 in the light). In the morpholino-injected group,
14/15 larvae had discharges during the light ON state; 7/15
larvae had spiking only during the 5-min light ON state,
and 10/15 showed spiking activity within the ﬁrst 3–5s
after the light ON. The average duration of any event
(spike or polyspike discharge) in the morpholino-injected
group fell during the light ON state (Fig. 3A), attributable
to the fact that morpholino-injected larvae also displayed
spontaneous polyspike discharges in the dark: the events
under light conditions were more heterogeneous (i.e. spon-
taneous polyspikes plus light-induced spiking), explaining
reduced average duration. The average number of events/
larva signiﬁcantly increased in the morpholino-injected
group in the light opposed to the dark period; this was
not seen in the control group (Fig. 3B). A similar pattern
was observed for cumulative duration of spiking activity
(Fig. 3C): morpholino-injected larvae showed a steep
increase in polyspike discharges in the light ON state, not
observed for controls. The larvae from the non-injected
control group also reacted to the light ON state by display-
ing an initial locomotor response, with 7/10 displaying
short spontaneous burst activity within 2–13s after the
light was switched on. However, the overall distribution
of event duration is different from that of morpholino-
injected larvae (Fig. 3D): the controls’ curve lies to
the left of the morpholino-injected curve, indicating that
the proportion of longer discharges is higher in the
morpholino-injected group.
Figure 1 Schematic of CHD2 illustrating its functional (chromo, DEXDc, DNA-binding and ATP helicase) domains, the lo-
cation of previously-reported variants and the unique variants in both cases and controls identiﬁed in this study.
Table 3 Odds ratio for association with unique variants
in CHD2 by phenotype, with 99% CI
P-value
(Fisher’s
exact;
2-tailed)
Odds
ratio
Lower
bound of
99% CI
Upper
bound of
99% CI
Whole photosensitive
epilepsy cohort
2.17  10
5 5.18 2.29 11.74
EMA alone 3.50  10
4 24.36 5.06 117.38
GGE excluding EMA 0.089 2.44 0.65 9.08
Focal epilepsies 0.021 9.40 1.45 61.01
Cases with PPR only 0.186 4.96 0.36 67.74
The associations with photosensitive epilepsy overall and with EMA alone are signiﬁ-
cant, as documented in the text. PPR = photoparoxysmal response.
CHD2 in photosensitive epilepsy BRAIN 2015: 138; 1198–1207 | 1203
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 Discussion
We show an enrichment of unique variants in CHD2 with
photosensitivity in the common epilepsies overall, identify-
ing CHD2 as a photosensitive epilepsy gene. We also
examined the distribution of unique variants by syndrome.
CHD2 is also the ﬁrst gene to be discovered for EMA, the
archetypal photosensitive epilepsy syndrome. In CHD2
encephalopathy, though published phenotypes can be difﬁ-
cult to interpret, the seizure type of absence seizures with
eyelid myoclonia, rather than the epilepsy syndrome, is seen
in as many as 8/23 (35%) patients with de novo CHD2
mutation or deletion (Veredice et al., 2009; Dhamija et al.,
2011; Capelli et al., 2012; Carvill et al., 2013; Che ´nier
et al., 2014; Lund et al., 2014). Together, these results
suggest that CHD2 is an important contributor to both
the absence seizures with eyelid myoclonia seizure type
and EMA epilepsy syndrome. For other epilepsy syn-
dromes, CHD2 variation over-representation in the photo-
sensitive GGE or the mixed cohort of photosensitive focal
epilepsies failed to meet the corrected threshold for signiﬁ-
cance. A single unique CHD2 variant was found in one
patient with photoparoxysmal response without seizures.
In view of the comparatively small sizes of these syndrome
cohorts, we can only conﬁdently exclude effects with odds
ratios greater than the upper limit for the 99% conﬁdence
intervals given in Table 3. Further studies in larger cohorts
of these phenotypes would seem warranted.
Previous studies of photoparoxysmal response support a
model of signiﬁcant genetic heterogeneity and an overall
complex genetic architecture (Sadleir et al., 2012; Verrotti
et al., 2012; Taylor et al., 2013): indeed, none of the
several linkage regions contain CHD2. Our ﬁndings con-
ﬁrm heterogeneity and complexity in the genetics of photo-
sensitivity, but also suggest a single gene may contribute to
photosensitivity in some cases. Two mutations we detected
are recurrent: p.Glu1412Glyfs*64, previously reported in
epileptic encephalopathy with marked photosensitivity
(Carvill et al., 2013); and p.Gln1392Thrfs*17, in Lennox-
Gastaut syndrome with photosensitivity (Lund et al., 2014).
The unique variants detected are, as a group, predicted to
be amongst the most deleterious variants possible (Kircher
et al., 2014) and CHD2 is amongst the genes least tolerant
of functional variation (Petrovski et al., 2013; Residual
Variation Intolerance Score 2.37).
CHD2 does not encode an ion channel, opening up new
avenues for research into cortical excitability. CHD2 is one
of nine genes from a highly-conserved protein family with a
unique domain combination: two N-terminal chromatin-
organization modiﬁer (chromo), SNF2-related helicase/
ATPase and DNA-binding domains (Woodage et al.,
1997; Schuster et al., 2002; Kulkarni et al., 2008). Chd2
knockdown zebraﬁsh have multiple developmental abnorm-
alities, abnormal movements and epileptiform discharges
(Suls et al., 2013). Disruption of Chd2 in mice causes em-
bryonic death in some heterozygote pups and a complex
phenotype including growth retardation and lordokyphosis
(Marfella et al., 2006; Kulkarni et al., 2008): epilepsy has
not yet been described. Interestingly, the reported human
mutations do not cluster to accessory domains of the pro-
tein and no obvious pattern has emerged. Recent data
demonstrated that the N-terminal region of CHD2 plays
an inhibitory role, reducing DNA afﬁnity and ATPase ac-
tivity which may confer speciﬁcity, while the C-terminus
enhances DNA binding and stimulates ATPase activity
Figure 2 Representative tectal ﬁeld recordings of 4-dpf zebraﬁsh larvae. Background fragment of non-treated wild-type control in the
dark (A); reaction of a non-injected ﬁsh to light ON - movement artefacts (wavy background) and a very short spike were observed (B); response
to light ON of the morpholino-injected larvae: signiﬁcantly more spiking activity is seen (C). The scale is the same for all three fragments.
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 (Liu et al., 2015). Additional studies investigating protein
interacting partners and post-translational modiﬁcations of
CHD2 will be necessary to understand how abnormal
CHD2 leads to photosensitive epilepsy.
Our zebraﬁsh data show that partial (50%) loss of
chd2 function causes photosensitivity. Although Suls et al.
(2013) showed chd2 knockdown could cause seizures,
photosensitivity was not studied. Although normal zebra-
ﬁsh show complex sensitivity to light (Moore and
Whitmore, 2014), and untreated larvae show minor sensi-
tivity to sudden exposure to light, morpholino-injected
larvae show signiﬁcantly more spiking activity on sudden
light exposure. Photosensitivity on constant, rather than
only ﬂickering, light exposure has been described in
humans (Oguni et al., 2001). The functional consequences
of each of the human mutations we detected is not known,
but some at least very probably lead to loss of function, as
caused by partial chd2 knockdown that results in markedly
enhanced photosensitivity in zebraﬁsh. Together, these data
strongly suggest that some human CHD2 mutations cause
photosensitivity.
There are potential limitations of our work. Different
sequencing platforms were used for the various studied
groups. However, we note that all unique variants in
cases were conﬁrmed by a second method, whereas for
ExAC controls we used a liberal threshold to maximize
sensitivity to unique variants, such that a proportion of
variants selected from ExAC will be false positive: the net
result of this overall conservative approach is only to
reduce study power. The ExAC cohort is also the biggest
relevant control data set available, and the most likely of
any existing data set to provide an accurate estimate of the
Figure 3 Electrographic activity of zebraﬁsh larvae with chd2 knockdown and light ON stimulus. Zebraﬁsh larvae (4 dpf) were kept
in the dark (or darkened environment, if not possible otherwise) for all groups in Danieau’s medium. Tectal ﬁeld recordings were performed for
the ﬁrst 5min in the dark and subsequently in light ON state for the following 5min in morpholino-injected larvae (n = 15) and non-injected larvae
(n = 10). A spiking episode, either spontaneous or evoked by light, was deﬁned as a paroxysm of high-frequency (200–500 Hz) activity with the
amplitude exceeding three times the background. Average duration of spiking events  SEM detected per condition is shown in A. Average
number of events per ﬁsh  SEM is shown in B. Cumulative duration of spiking activity per ﬁsh as seconds  SEM is shown in C. Cumulative
frequency distribution of spiking episodes is shown in D: morpholino-injected larvae show more activity than any of the non-injected controls, and
a higher photosensitivity (curve shift to the right in the light compared to the dark recordings). *P50.05 and **P50.01 Mann-Whitney test.
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 true frequency of unique variation in CHD2 in a popula-
tion not enriched for photosensitive epilepsy. Taking all
these factors into account, the use of different platforms
is very unlikely to have generated false positive results—
indeed, we are more likely to have underestimated unique
variant numbers in cases. It is also possible that our choice
of statistical test may have missed a true association
between rare variation in CHD2 and GGE (irrespective
of photoparoxysmal response or photosensitivity), and we
did not test whether CHD2 variation contributes to
epilepsy more broadly: we therefore cannot exclude the
possibility that rare CHD2 variation contributes to epilepsy
per se. Lack of parental samples meant we could only con-
ﬁrm variants were de novo in two patients. Family samples
were only available in one other case (Case 9): the variant
was inherited from a clinically-unaffected mother in whom
no EEG studies had been carried out.
Our results provide evidence for a speciﬁc gene in a par-
ticular trait in epilepsy. Understanding the genetic basis of
the photosensitivity trait is a ﬁrst step to elucidating the
biology that underlies photoparoxysmal response and its
relation to epilepsy. Human photosensitive epilepsy para-
digms have facilitated epilepsy treatment discoveries
(French et al., 2014): understanding photoparoxysmal
response biology may increase the value of these para-
digms. Our ﬁndings may also provide new directions for
understanding human cortical excitability.
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